Back to top

Image: Bigstock

Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and Acceleron Pharma Inc. , may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Acceleron Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for XLRN in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 87 cents per share for XLRN, compared to a broader Zacks Consensus Estimate of a loss of 96 cents per share. This suggests that analysts have very recently bumped up their estimates for XLRN, giving the stock a Zacks Earnings ESP of +9.14% heading into earnings season.

Acceleron Pharma Inc. Price and EPS Surprise

Acceleron Pharma Inc. Price and EPS Surprise

Acceleron Pharma Inc. price-eps-surprise | Acceleron Pharma Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that XLRN has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1(Strong Buy) Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Acceleron Pharma, and that a beat might be in the cards for the upcoming report.